Sexually Transmitted Diseases

A recent report discusses the expansion of pre-exposure prophylaxis into the 35 PEPFAR supported early program adopters from October 2016 to September 2018.

New research pinpoints some of the factors involved in HIV reemergence after cessation of antiretroviral therapy, as well as possible ways to stop the process.

Clinicians accustomed to HIPAA guidelines may not be aware of changes in confidentiality when they make contact with school health care services.

Jason Tokumoto, MD, reflects on the ways people respond to HIV diagnosis.

Concerns over the possibility of increased neural-tube defects and weight gain on dolutegravir are outweighed by the much lower rates of HIV transmission from mother to baby than are seen with efavirenz.

A new study has identified that misinformation and limited clinician communication around HPV risk among young men who have sex with men some of the barriers to HPV vaccination.

Clinicians must identify when additional pounds cross the line of diminishing return.

People living with HIV who don’t receive early intervention and primary care end up with a disproportionate share of health care costs, according to a new study that examined barriers to care and costs at a Dublin hospital.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

The rising price of antiretroviral therapy for people living with HIV in the United States is a barrier to adherence. It also blunts efforts to achieve higher rates of viral suppression.

A new retrospective study provides more evidence that a single HPV vaccine dose may be effective in preventing cervical cancer.

February 7th is commemorated each year to highlight the impact that HIV and AIDS has on the black or African American population in the United States.

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

NIAID and partner organizations have discontinued HIV vaccination in a South Africa based experimental trial.

Andrea L. Cox, MD, PhD, discusses the implications of discovering that an experimental vaccine was not effective at preventing chronic hepatitis C virus.

A new study provides evidence that more needs to be done to meet the needs of children in rural Zimbabwe who are exposed to HIV.

Regardless of HIV status, frailty was a strong predictor for mortality and comorbidity for middle-aged adults.

Through the platform providers, consumers, and procurers will have access to full prescribing inserts and FDA-reviewed product labeling which will provide additional important information to patients and providers.

Daniel Chastain, PharmD, BCIDP, discusses how antiretroviral stewardship might practically be implemented in the context that antimicrobial stewardship as a whole is often underdeveloped.

Max Brito, MD, MPH, explains the value of bringing safe, confidential, and non-stigmatizing HIV treatment to the community at IDWeek2019.

Standalone HIV testing centers in San Diego County, California, have been largely effective at reaching people at high risk of infection, according to a new study that also identified areas where targeted testing efforts may be beneficial.

Babies born with HIV benefit from beginning ART with days—not weeks—of birth.

A study has revealed the ways Mycoplasma genitalium competes with host organism cells for essential metal nutrients.

Andrea L. Cox, MD, PhD, compares the rates of hepatitis C and hepatitis B diagnoses since the start of the opioid epidemic.

Public Health England reported the promising news that new HIV transmission in the UK continued to decline in 2018.